You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 8,624,079

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,624,079

Title:	Knockin mouse with a disruption in a PXR gene expressing human PXR
Abstract:	The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. One aspect of the invention relates to the use of a human DNA sequence comprising at least part of introns 6 and/or 7 of the human PXR gene.
Inventor(s):	Wolf; Charles Roland (Dundee, GB), Scheer; Nico (Cologne, DE)
Assignee:	ITI Scotland Limited (Glasgow, GB)
Application Number:	12/602,723
Patent Claims:	1. A transgenic mouse, or tissue or cells derived therefrom, whose genome comprises: (i) an annulled pregnane X receptor transcription factor (PXR) gene; and (ii) a DNA sequence encoding a human PXR gene knocked-into the mouse PXR locus, wherein: a. said DNA sequence has an intron-exon structure and comprises at least part of intron 6 and/or intron 7 of the human PXR gene; and b. expression of the human PXR gene is under the control of a mouse PXR promoter. 2. The transgenic mouse, or tissue or cells derived therefrom according to claim 1, wherein said human DNA sequence comprises at least part of introns 4, 5, 6, and/or 7 of the human PXR gene. 3. The transgenic mouse, or tissue or cells derived therefrom according to claim 1, wherein said DNA sequence comprises introns 4-8 of the human PXR gene. 4. The transgenic mouse, or tissue or cells derived therefrom according to claim 1, wherein said DNA sequence further comprises at least part of introns 2, 3, 6, 7, and/or 8 of the human PXR gene. 5. The transgenic mouse, or tissue or cells derived therefrom according to claim 1, wherein said human DNA sequence comprises introns 2-8 of the human PXR gene. 6. The transgenic mouse, or tissue or cells derived therefrom according to claim 1, wherein said human DNA sequence comprises a sequence that is at least 70% identical to the sequence of SEQ ID NO:2 or the sequence of SEQ ID NO:3.

Details for Patent 8,624,079

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2027-06-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2027-06-04
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2027-06-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.